QuantRx Biomedical Corporation (QTXB)
QuantRx Biomedical Corporation operates in the Medical - Instruments & Supplies industry of the Healthcare sector, headquartered in Tualatin, OR, US. The stock last traded at $0.00, up 400.00% on the session, giving a market capitalisation of $118,045. On trailing twelve-month figures it carries a trailing P/E of -0.08, a net margin of 0.0%. Its beta of -2.04 implies it has historically moved less than the broad market.
QuantRx Biomedical Corporation is engaged in the creation and marketing of its patented miniature pads (PADs) and related over-the-counter (OTC) products within the United States. Additionally, the company is developing genomic diagnostic tools for the laboratory market, leveraging its proprietary lateral flow technologies, including the RapidSense single-step lateral flow test. The company's PAD products are designed to address a range of medical conditions such as hemorrhoids, mild vaginal infections, urinary incontinence, menstrual hygiene, and other general medical needs. Key offerings include InSync, an interlabial pad for feminine hygiene. Another significant product is the Unique miniform, which comes in two forms: a medicated pad providing temporary relief from the itching and discomfort associated with hemorrhoids and minor vaginal infections, and an unmedicated pad for daily management of light urinary, vaginal, or anal leakage. Other treated miniform products are also part of their portfolio. Established in 1986, QuantRx Biomedical Corporation is headquartered in Tualatin, Oregon.
QuantRx Biomedical Corporation is most often compared with the following Healthcare names: